AMPH - Bathi resik saben saham (EPS TTM) Amphastar Pharmaceuticals Inc

The production of complex injectable generics provides Amphastar Pharmaceuticals (AMPH) with high margins and operational leverage as volumes grow. However, FDA delays and price erosion create risks for profitability. The company is implementing innovative peptides and drug delivery systems. The current rolling annual EPS reflects earnings dynamics, with the current mark equal to 2.20.

Trailing twelve-month net income per share reflects the actual efficiency of capital generation per common share, eliminating the volatility of quarterly reports. For Amphastar Pharmaceuticals (AMPH), this trailing annual earnings per share demonstrates how successfully the transition to proprietary drug delivery systems mitigates the risks of dependence on a narrow segment of injectable generics, thereby determining the fair value of the business.